Bispecific antibody (Multispecific) · Immune activation, directed at NKp46 (NCR1), CD16a (FcgammaRIIIa) (FCGR3A) and CD20 (MS4A1) · developed by Innate Pharma
Zemlikafusp alfa (IPH6501) is a tetra-specific NK cell engager built from antibody fragments against NKp46 and CD16a on natural killer cells and CD20 on tumor cells, plus a non-alpha interleukin-2 variant that binds the IL-2 receptor beta chain (CD122). It bridges NK cells to CD20-expressing cancer cells to stimulate NK cell activation and cytotoxicity. It is being studied in non-Hodgkin lymphoma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06088654 | Phase 1/2 | Non Hodgkin Lymphoma | Terminated | IPHA |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Non Hodgkin Lymphoma
Updated Oct 18, 2026. Something wrong or missing? Report it on the IPHA page.
See IPHA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
IPHA catalysts and pipeline →